Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?

@article{Martelli2011MethotrexatePI,
  title={Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?},
  author={Nicolas Martelli and Olivier Mathieu and Genevi{\`e}ve Margueritte and Marie C{\'e}cile Bozonnat and J -P Daur{\`e}s and Françoise Bressolle and Dominique Hillaire-Buys and H{\'e}l{\`e}ne Peyri{\`e}re},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2011},
  volume={36 2},
  pages={237-45}
}
WHAT IS KNOWN AND OBJECTIVE In industrialized countries, acute lymphoblastic leukaemia (ALL) is the most frequent cancer in children aged less than 15 years. High-dose methotrexate is a common component of many chemotherapeutic protocols for childhood with ALL. Our objective was to retrospectively evaluate the pharmacokinetics and plasma levels of high-dose methotrexate as it relates to event-free survival (EFS) in children with ALL. METHODS Relapsed patients and subjects in EFS were compared… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.

NCI monographs : a publication of the National Cancer Institute • 1987
View 4 Excerpts
Highly Influenced

Pharmacogenomics of acute leukemia.

Pharmacogenomics • 2007
View 1 Excerpt

Treatment of acute lymphoblastic leukemia.

The New England journal of medicine • 2006
View 2 Excerpts

Similar Papers

Loading similar papers…